Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India.
Adenocarcinoma of Lung
/ drug therapy
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
DNA Mutational Analysis
ErbB Receptors
/ genetics
Female
Follow-Up Studies
Humans
India
/ epidemiology
Kaplan-Meier Estimate
Lung
/ pathology
Lung Neoplasms
/ drug therapy
MAP Kinase Signaling System
/ genetics
Male
Middle Aged
Mutation
Neoplasm Grading
Progression-Free Survival
Proto-Oncogene Proteins B-raf
/ genetics
Proto-Oncogene Proteins p21(ras)
/ genetics
Journal
Current problems in cancer
ISSN: 1535-6345
Titre abrégé: Curr Probl Cancer
Pays: United States
ID NLM: 7702986
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
20
08
2018
revised:
13
10
2018
accepted:
04
12
2018
pubmed:
29
12
2018
medline:
2
9
2020
entrez:
29
12
2018
Statut:
ppublish
Résumé
Mitogen-Activated Protein (MAP) Kinase pathway involves several oncogenic genes which can serve as potential targets for therapy. Therefore, aim of the present study is to analyze mutations in the MAP Kinase pathway in pulmonary adenocarcinoma (ADCA) of Indian patients along with clinico-pathologic correlation and determination of the survival status in patients receiving therapy. Blocks and slides of 125 pulmonary ADCA of last 5 years were retrieved. Histo-morphology and tumor content were determined. EGFR, KRAS, BRAF and MEK1 genes were analyzed using Sanger sequencing and Real-time polymerase chain reaction (PCR). Clinico-pathologic correlation and survival analysis were performed. Fifty-eight (46.4%) patients harbored genetic mutations of which 49 had single somatic mutations, 5 had multiple exonic and 4 showed coexisting EGFR and KRAS mutations. EGFR mutations were seen in 24.8%, KRAS in 19.2% and BRAF (non-V600E) in 2.4% cases. There was no difference in progression-free survival of wild- type/single mutations when compared with multiple/ coexisting mutations (P = 0.09). However, the P value may indicate borderline correlation. To conclude, EGFR and KRAS mutations may coexist in the same patient in lung ADCA. Multiple exonic mutations of KRAS gene formed substantial percentage of our cohort, requiring further exploration. Lung ADCA harbouring BRAF mutations are commonly non-V600E. Testing of all major genetic driver mutations of lung ADCA irrespective of histology and other demographic characteristics is necessary.
Identifiants
pubmed: 30591192
pii: S0147-0272(18)30266-6
doi: 10.1016/j.currproblcancer.2018.12.003
pmc: PMC6579716
mid: NIHMS1015333
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
KRAS protein, human
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
391-401Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK089502
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK026523
Pays : United States
Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.
Références
Oncol Lett. 2016 Apr;11(4):2552-2558
pubmed: 27073516
Mol Cancer. 2016 Oct 18;15(1):63
pubmed: 27756406
Pharmacol Ther. 2004 Apr;102(1):37-46
pubmed: 15056497
Clinics (Sao Paulo). 2012;67(5):419-24
pubmed: 22666783
J Thorac Oncol. 2013 Jan;8(1):52-61
pubmed: 23242438
Expert Opin Ther Targets. 2012 Jan;16(1):103-19
pubmed: 22239440
Medicine (Baltimore). 2017 Apr;96(14):e6552
pubmed: 28383426
J Thorac Oncol. 2011 Nov;6(11):1955-9
pubmed: 22005474
Am J Surg Pathol. 2008 Jun;32(6):810-27
pubmed: 18391747
Oncol Lett. 2017 Dec;14(6):6525-6532
pubmed: 29163686
Cancer. 2012 Feb 1;118(3):729-39
pubmed: 21720997
Cancer Res. 2005 Jun 15;65(12):5076-83
pubmed: 15958551
Clin Cancer Res. 2006 Apr 15;12(8):2538-44
pubmed: 16638863
J Thorac Oncol. 2017 Jun;12(6):963-973
pubmed: 28189832
Mol Clin Oncol. 2014 Mar;2(2):187-196
pubmed: 24649331
Thorac Cancer. 2014 Mar;5(2):126-32
pubmed: 26766989
APMIS. 2016 Oct;124(10):832-8
pubmed: 27500967
Clin Cancer Res. 2006 Mar 1;12(5):1647-53
pubmed: 16533793
Oncogene. 2007 May 14;26(22):3291-310
pubmed: 17496923
J Thorac Oncol. 2013 Apr;8(4):461-8
pubmed: 23486266
Cancer. 2011 Sep 15;117(18):4257-66
pubmed: 21387273
Int J Colorectal Dis. 2011 Oct;26(10):1241-8
pubmed: 21603900
Lung India. 2016 May-Jun;33(3):257-66
pubmed: 27185988
Anticancer Res. 2010 May;30(5):1667-71
pubmed: 20592359
Oncogene. 2007 May 14;26(22):3279-90
pubmed: 17496922
Indian J Med Res. 2016 Mar;143(3):308-14
pubmed: 27241644
Med Oncol. 2016 Oct;33(10):117
pubmed: 27637917
Cancer. 2014 May 15;120(10):1471-81
pubmed: 24700479
J Cancer Res Clin Oncol. 2014 Mar;140(3):453-60
pubmed: 24442099
Acta Cytol. 2017;61(6):455-461
pubmed: 28848083
Pathol Oncol Res. 2015 Jul;21(3):675-87
pubmed: 25637496
Clin Cancer Res. 2009 Jul 15;15(14):4554-60
pubmed: 19584155
J Thorac Oncol. 2013 Sep;8(9):1190-5
pubmed: 23787801
J Thorac Oncol. 2012 Feb;7(2):323-30
pubmed: 22237264
Cancer Res. 2004 Dec 15;64(24):8919-23
pubmed: 15604253
Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S17-27
pubmed: 22443084
Oncotarget. 2016 Apr 26;7(17):24172-8
pubmed: 26992220
J Thorac Oncol. 2011 Apr;6(4):707-15
pubmed: 21258250
J Clin Oncol. 2011 May 20;29(15):2046-51
pubmed: 21483012
PLoS One. 2014 Jun 30;9(6):e101354
pubmed: 24979348
Br J Cancer. 2014 Nov 25;111(11):2203-4
pubmed: 25117816
Clin Cancer Res. 2012 Nov 15;18(22):6169-77
pubmed: 23014527
J Pathol Transl Med. 2016 May;50(3):197-203
pubmed: 27086595
Mol Cancer. 2018 Feb 19;17(1):33
pubmed: 29455666
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Mod Pathol. 2013 Oct;26(10):1307-19
pubmed: 23619604
PLoS One. 2013 Apr 19;8(4):e61561
pubmed: 23620765